Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1993 May;61(5):1636–1640. doi: 10.1128/iai.61.5.1636-1640.1993

Complement resistance of pathogenic Entamoeba histolytica mediated by trypsin-sensitive surface component(s).

C Hamelmann 1, B Urban 1, B Foerster 1, R D Horstmann 1
PMCID: PMC280745  PMID: 8478051

Abstract

Pathogenic forms of the protozoan parasite Entamoeba histolytica were reported previously to resist the cytolytic effect of the alternative complement pathway (AP) only temporarily during exposure to complement. In contrast, nonpathogenic forms of E. histolytica had been found to show AP resistance as a stable property. We studied the mechanisms of AP resistance of the two forms. Upon exposure to AP activity, resistant pathogenic or nonpathogenic forms bound significantly less C3 products than complement-sensitive pathogenic amebae, indicating that the two resistant forms both inhibited AP amplification. Various enzymatic treatments and inhibition of membrane mobility by cytochalasin B and glutaraldehyde fixation showed that the mechanisms of AP inhibition differed between pathogenic and nonpathogenic forms; in contrast to nonpathogenic forms, pathogenic amebae required intact membrane mobility and a trypsin-sensitive surface component(s) to inhibit AP activation.

Full text

PDF
1636

Images in this article

1638Image
on p.1638

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AMINOFF D. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem J. 1961 Nov;81:384–392. doi: 10.1042/bj0810384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aust-Kettis A., Sundqvist K. G. Dynamics of the interaction between Entamoeba histolytica and components of the immune response. I. Capping and endocytosis; influence of inhibiting and accelerating factors; variation of the expression of surface antigens. Scand J Immunol. 1978;7(1):35–44. doi: 10.1111/j.1365-3083.1978.tb00424.x. [DOI] [PubMed] [Google Scholar]
  3. Aust-Kettis A., Sundqvist K. G. Dynamics of the interaction between Entamoeba histolytica and components of the immune response. Scand J Immunol. 1980;12(5):443–451. doi: 10.1111/j.1365-3083.1980.tb00088.x. [DOI] [PubMed] [Google Scholar]
  4. Calderon J., Schreiber R. D. Activation of the alternative and classical complement pathways by Entamoeba histolytica. Infect Immun. 1985 Nov;50(2):560–565. doi: 10.1128/iai.50.2.560-565.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Calderon J., Tovar R. Loss of susceptibility to complement lysis in Entamoeba histolytica HM1 by treatment with human serum. Immunology. 1986 Jul;58(3):467–471. [PMC free article] [PubMed] [Google Scholar]
  6. Clark C. G., Diamond L. S. Ribosomal RNA genes of 'pathogenic' and 'nonpathogenic' Entamoeba histolytica are distinct. Mol Biochem Parasitol. 1991 Dec;49(2):297–302. doi: 10.1016/0166-6851(91)90073-f. [DOI] [PubMed] [Google Scholar]
  7. De Petris S. Inhibition and reversal of capping by cytochalasin B, vinblastine and colchicine. Nature. 1974 Jul 5;250(461):54–56. doi: 10.1038/250054a0. [DOI] [PubMed] [Google Scholar]
  8. Diamond L. S., Harlow D. R., Cunnick C. C. A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba. Trans R Soc Trop Med Hyg. 1978;72(4):431–432. doi: 10.1016/0035-9203(78)90144-x. [DOI] [PubMed] [Google Scholar]
  9. Fraker P. J., Speck J. C., Jr Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978 Feb 28;80(4):849–857. doi: 10.1016/0006-291x(78)91322-0. [DOI] [PubMed] [Google Scholar]
  10. Hamelmann C., Foerster B., Burchard G. D., Horstmann R. D. Lysis of pathogenic and nonpathogenic Entamoeba histolytica by human complement: methodological analysis. Parasite Immunol. 1992 Jan;14(1):23–35. doi: 10.1111/j.1365-3024.1992.tb00003.x. [DOI] [PubMed] [Google Scholar]
  11. Hammer C. H., Wirtz G. H., Renfer L., Gresham H. D., Tack B. F. Large scale isolation of functionally active components of the human complement system. J Biol Chem. 1981 Apr 25;256(8):3995–4006. [PubMed] [Google Scholar]
  12. Huldt G., Davies P., Allison A. C., Schorlemmer H. U. Interactions between Entamoeba histolytica and complement. Nature. 1979 Jan 18;277(5693):214–216. doi: 10.1038/277214a0. [DOI] [PubMed] [Google Scholar]
  13. Law S. K., Lichtenberg N. A., Levine R. P. Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol. 1979 Sep;123(3):1388–1394. [PubMed] [Google Scholar]
  14. Mogyoros M., Calef E., Gitler C. Virulence of Entamoeba histolytica correlates with the capacity to develop complement resistance. Isr J Med Sci. 1986 Dec;22(12):915–917. [PubMed] [Google Scholar]
  15. Morgan B. P., Dankert J. R., Esser A. F. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol. 1987 Jan 1;138(1):246–253. [PubMed] [Google Scholar]
  16. Müller-Eberhard H. J. Molecular organization and function of the complement system. Annu Rev Biochem. 1988;57:321–347. doi: 10.1146/annurev.bi.57.070188.001541. [DOI] [PubMed] [Google Scholar]
  17. Ortiz-Ortiz L., Capin R., Capin N. R., Sepúlveda B., Zamacona G. Activation of the alternative pathway of complement by Entamoeba histolytica. Clin Exp Immunol. 1978 Oct;34(1):10–18. [PMC free article] [PubMed] [Google Scholar]
  18. Podack E. R., Kolb W. P., Esser A. F., Müller-Eberhard H. J. Structural similarities between C6 and C7 of human complement. J Immunol. 1979 Sep;123(3):1071–1077. [PubMed] [Google Scholar]
  19. Reed S. L., Gigli I. Lysis of complement-sensitive Entamoeba histolytica by activated terminal complement components. Initiation of complement activation by an extracellular neutral cysteine proteinase. J Clin Invest. 1990 Dec;86(6):1815–1822. doi: 10.1172/JCI114911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sargeaunt P. G., Williams J. E., Grene J. D. The differentiation of invasive and non-invasive Entamoeba histolytica by isoenzyme electrophoresis. Trans R Soc Trop Med Hyg. 1978;72(5):519–521. doi: 10.1016/0035-9203(78)90174-8. [DOI] [PubMed] [Google Scholar]
  21. Tannenbaum J. Approaches to the molecular biology of cytochalasin action. Front Biol. 1978;46:521–559. [PubMed] [Google Scholar]
  22. Tannich E., Burchard G. D. Differentiation of pathogenic from nonpathogenic Entamoeba histolytica by restriction fragment analysis of a single gene amplified in vitro. J Clin Microbiol. 1991 Feb;29(2):250–255. doi: 10.1128/jcm.29.2.250-255.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tannich E., Horstmann R. D., Knobloch J., Arnold H. H. Genomic DNA differences between pathogenic and nonpathogenic Entamoeba histolytica. Proc Natl Acad Sci U S A. 1989 Jul;86(13):5118–5122. doi: 10.1073/pnas.86.13.5118. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES